Compare AMRC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | 1601 | 133 |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.7B |
| IPO Year | 2010 | N/A |
| Metric | AMRC | MPLT |
|---|---|---|
| Price | $21.12 | $10.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $37.88 | $32.67 |
| AVG Volume (30 Days) | 439.7K | ★ 509.6K |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | N/A |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.76 | N/A |
| 52 Week Low | $15.52 | $12.24 |
| 52 Week High | $44.93 | $40.43 |
| Indicator | AMRC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 21.32 |
| Support Level | N/A | N/A |
| Resistance Level | $33.98 | $20.73 |
| Average True Range (ATR) | 1.20 | 2.77 |
| MACD | -0.17 | -2.03 |
| Stochastic Oscillator | 3.12 | 0.79 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.